Department of Leukemia, MD Anderson Cancer Center, Houston, TX
Naval Guastad Daver , John Affinito , Hongliang Cai , Hanna Dobrowolska , Ken Eguchi , Zijing Zhang , Jay Stoudemire , Akinobu Watanabe , Pablo Martinez , Philip Komarnitsky
Background: DSP-5336, a menin MLL interaction inhibitor, elicited antitumor activity in MLL–r or NPM1m acute leukemia models in vitro and in vivo. An open-label, single-arm, phase 1/2 study (NCT04988555) will evaluate the safety and efficacy of DSP-5336 and determine the recommended phase 2 dose (RP2D) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) or acute lymphocytic leukemia (ALL). Methods: Patients aged ≥18 y with R/R AML, ALL, or acute leukemia of ambiguous lineage after ≥1 line of standard therapy, ECOG PS 0–2, and adequate organ function are eligible. Patients will receive DSP-5336 twice daily for 28 d/cycle. In phase 1, there will be two parallel escalation cohorts: patients who do not receive concomitant azole antifungal medication and patients who receive antifungal azoles (ie, posaconazole, voriconazole, or fluconazole); 21–30 patients will be enrolled during phase 1 into multiple ascending dose levels. Dose escalation will use a Bayesian logistic regression model. Phase 2 will enroll two arms: R/R AML with MLL–r and R/R AML with NPM1m (10–20 patients/arm). Patients will be treated at the RP2D to evaluate clinical activity and safety. Clinical trial information: NCT04988555.
Endpoints | Phase 1 (R/R AML or ALL) | Phase 2 (R/R AML with MLL–r and/or NPM1m) |
---|---|---|
Primary | Safety DLTs; TEAEs, SAEs; changes in vital signs, PEs, clinical lab values, ECG & ECHO parameters | Clinical Responses CR (MRD−), CR, CRh, CRi, PR, MLFS, CR + CRh, OR (=CR [MRD−] + CR + CRh + CRi + MLFS + PR), DOR, TTR, time to CR, TI, OS, EFS, RFS |
Tolerability Dose interruptions, reductions, and/or discontinuations | ||
Biologic efficacy | ||
Secondary | Pharmacokinetics Plasma DSP-5336 concentration-time profiles and PK parameters | Safety DLTs; TEAEs, SAEs; changes in vital signs, PEs, clinical lab values, ECG parameters |
Clinical Responses CR (MRD−), CR, CRh, CRi, PR, MLFS, OR (=CR [MRD−] + CR + CRh + CRi + MLFS + PR), time to CR, DOR, TTR, TI, OS, RFS, EFS | Tolerability Dose interruptions, reductions, and/or discontinuations | |
Cardiac Safety QT interval changes and morphology | ||
Exploratory | Pharmacodynamics Changes in expression levels of leukemogenesis and myeloid differentiation genes |
Definitions: AE, adverse event; CR, complete response; CRh, complete remission with partial hematologic recovery; CRi, complete remission with incomplete hematologic recovery; DLT, dose-limiting toxicity; DOR, duration of response; ECG, electrocardiogram; ECHO, echocardiogram; EFS, event-free survival; MLFS, morphologic leukemia-free state; MRD, minimal residual disease; OR, objective response; PE, physical examination; PR, partial response; RFS, relapse-free survival; SAE, serious AE; TEAE, treatment-emergent AE; TI, transfusion independence; TTR, time to response.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Justin M. Watts
2023 ASCO Annual Meeting
First Author: Nicholas James Short
2022 ASCO Annual Meeting
First Author: L Elizabeth Budde
2023 ASCO Annual Meeting
First Author: Nicholas James Short